LL-37 (Cathelicidin): Mechanistic Overview
internal_protocol · mechanistic · status: needs_provider_review
Metadata
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
Embedding: pending
File: signed link
Summary (generated — provider review required)
LL-37 is the only human cathelicidin-derived antimicrobial peptide and a central effector of innate immunity. It is generated by proteolytic cleavage of the hCAP18 precursor and is expressed by neutrophils, epithelial cells, and macrophages. Mechanism.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (4) · phenotypes (0)
evidence_reference, mechanism, safety_reference, dosing_reference
Evidence claims (8) · review items (2)
mechanism · pending
It is generated by proteolytic cleavage of the hCAP18 precursor and is expressed by neutrophils, epithelial cells, and macrophages.
mechanism · pending
Mechanism.
mechanism · pending
Beyond direct killing, it is strongly immunomodulatory: it neutralizes lipopolysaccharide, recruits immune cells via formyl peptide receptors, and influences cytokine signaling.
mechanism · pending
It also has reported roles in angiogenesis and re-epithelialization during wound healing, and may interfere with bacterial biofilm formation.
mechanism · pending
In complex chronic illness, interest centers on its antimicrobial and biofilm-modulating properties and its position at the interface of host defense and inflammation.
mechanism · pending
Vitamin D status is a known upstream regulator of cathelicidin expression.
safety · pending
Safety considerations.
dosing · pending
This summary is mechanistic background for provider review and is not a treatment recommendation or dosing guidance.
Extracted chunks (1)
185 approx tokens across 1 chunks.